Acarbose ameliorates atherogenecity of low-density lipoprotein in patients with impaired glucose tolerance

Inoue, Ituro; Shinoda, Yasutoshi; Nakano, Takamitsu; Sassa, Masatoshi; Goto, Seiichi; Awata, Takuya; Komoda, Tsugikazu; Katayama, Shigehiro

doi:10.1016/j.metabol.2006.03.002

Cited by 32 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The demographic and blood biochemistry data of the subjects at baseline and at the end of the study are reported elsewhere [13]. Briefly, there were no significant differences in the data between the 2 groups.…”

Section: Resultsmentioning

confidence: 99%

Acarbose improves fibrinolytic activity in patients with impaired glucose tolerance

et al. 2006

Self Cite

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Acarbose improves fibrinolytic activity in patients with impaired glucose tolerance

et al. 2006

Self Cite

View full text Add to dashboard Cite

“…This is also supported by mechanistic studies showing that in subjects with IGT, acarbose, through a lowering of PPPG, resulted in a lowering of PPPG-associated rise in oxidative stress markers [40], in inflammatory markers (Lu, Personal communication), in procoagulation markers [41], and in endothelial dysfunction [42]. However, definite proof has to come from a prospective well-powered study whose objective will be the effect of acarbose on cardiovascular events in subjects with IGT.…”

Section: Efficacy Of Agis In the Prevention Of Vascular Complicationsmentioning

confidence: 85%

Who should benefit from the use of alpha-glucosidase inhibitors?

Godbout¹,

Chiasson

2007

Curr Diab Rep

View full text Add to dashboard Cite

Although most commonly used drugs such as biguanides, sulfonylureas, and more recently, thiazolidinediones, are effective in controlling fasting hyperglycemia, a high percentage of patients have sustained elevated hemoglobin A(1c) because of persistent elevation of postprandial plasma glucose (PPPG). alpha-Glucosidase inhibitors (AGIs) specifically target PPPG. AGIs have been shown in several randomized controlled trials to be effective in controlling blood glucose, whether they are used as monotherapy or in combination with other antidiabetic medications. Among the AGIs, acarbose has also been shown to decrease the risk of progressing to diabetes in subjects with impaired glucose tolerance (IGT). Studies have also suggested that acarbose could decrease the risk of cardiovascular disease, both in IGT and in diabetes. Furthermore, AGIs are very safe and are nontoxic drugs. Their only side effects are gastrointestinal, such as flatulence and diarrhea; however, these can be minimized by the "start low, go slow" approach. AGIs should be considered whenever postprandial hyperglycemia is the dominant metabolic abnormality.

show abstract

“…However, recently published investigations in patients with IGT analyzing LDLsubfractions reveal a decrease in small dense LDL [39]. No significant effects have been shown on HDL-cholesterol in the STOP-NIDDM study [29] and the MeRIA meta-analysis [36].…”

Section: Synergistic Effects On Metabolic Syndromementioning

confidence: 96%